Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage precision oncology company that reports frequent updates related to its efforts to develop therapies for RAS/MAPK pathway-driven cancers. News about Erasca often centers on progress within its RAS-targeting franchise, including clinical, preclinical, regulatory, and intellectual property developments.
Investors following ERAS news can expect detailed announcements on the advancement of the company’s key product candidates, ERAS-0015 and ERAS-4001. Erasca issues releases on milestones such as investigational new drug (IND) clearances, initiation and progress of Phase 1 trials, and early clinical observations in patients with RAS-mutant and KRAS-mutant solid tumors. The company also reports on patent issuances that extend composition of matter protection for its molecules and on scientific presentations at major oncology and healthcare conferences.
Erasca’s news flow includes quarterly business updates and financial results, typically accompanied by commentary from management on the status of the AURORAS-1 and BOREALIS-1 trials, cash resources, and research and development priorities. The company additionally announces participation in investor conferences hosted by firms such as J.P. Morgan, Evercore, Guggenheim, Stifel, Jefferies, Goldman Sachs, and Morgan Stanley, where its leadership discusses strategy and pipeline progress.
For readers tracking ERAS, this news stream provides insight into how Erasca is advancing its clinical-stage programs targeting RAS and KRAS, how it is building its intellectual property position, and how management frames the opportunities and risks associated with its focus on RAS/MAPK pathway-driven cancers.
Erasca, Inc. (Nasdaq: ERAS) announced initial Phase 1/1b data for its ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601, showcasing safe profiles for potential combination therapies in solid tumors. ERAS-801, a CNS-penetrant EGFR inhibitor, shows enhanced anti-tumor activity over osimertinib in preclinical models. New KRAS G12D inhibitors demonstrate significant tumor growth inhibition. The company will present findings at the 34th EORTC-NCI-AACR Symposium in October 2022, with further data expected in 2023, highlighting ongoing advancements in their oncology pipeline.
Erasca, Inc. (Nasdaq: ERAS), a company dedicated to precision oncology, will participate in the Bank of America Securities Precision Oncology Conference on October 3, 2022, at 3:40 PM ET. CEO Jonathan E. Lim and CFO David M. Chacko will engage in a virtual fireside chat and one-on-one investor meetings. A live webcast will be available, with an archived replay until January 3, 2023. Erasca aims to innovate therapies for RAS/MAPK pathway-driven cancers, leveraging a strong pipeline and expert advisory board to achieve its mission of erasing cancer.
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced its participation in the Morgan Stanley Global Healthcare Conference. On September 14, 2022, at 12:55 PM ET, CEO Jonathan E. Lim, M.D., and CFO David M. Chacko, M.D., will engage in a fireside chat at Sheraton Hotel, New York. They will also conduct one-on-one investor meetings. A live webcast will be available, with an archived replay accessible until December 14, 2022. Erasca is focused on therapies for RAS/MAPK pathway-driven cancers, aiming to develop innovative cancer treatments.
Erasca, a clinical-stage precision oncology company, reported promising Phase 1/1b data for its ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in treating RAS/MAPK-altered solid tumors. The retrospective analysis revealed that 23% of patients with non-CRC solid tumors and 44% of those with BRAF-driven tumors responded to these agents. Both drugs demonstrated favorable safety profiles, supporting their combination in upcoming trials. The initiation of the ERAS-007 plus ERAS-601 MAPKlamp trial is anticipated in the first half of 2023.
Erasca, Inc. (Nasdaq: ERAS) will host a virtual research and development day on September 7, 2022, featuring key opinion leader Dr. David Hong from MD Anderson Cancer Center. The event will present preliminary clinical data for Erasca's lead candidates, the ERK1/2 inhibitor ERAS-007 and the SHP2 inhibitor ERAS-601, targeting advanced solid tumors influenced by the RAS/MAPK pathway. Participants can register online for the event, which will include a live Q&A session.
Erasca, Inc. (Nasdaq: ERAS) has entered a five-year collaboration with The University of Texas MD Anderson Cancer Center to evaluate multiple agents targeting the RAS/MAPK pathway. The partnership's initial focus is on ERAS-007, an ERK1/2 inhibitor, and ERAS-601, a SHP2 inhibitor. These will be combined in the first MAPKlamp approach. Ongoing clinical trials of these agents will target various cancers, including non-small cell lung cancer and gastrointestinal malignancies. The collaboration aims to enhance the clinical development of Erasca's pipeline in addressing significant cancer treatment challenges.
Erasca, Inc. (Nasdaq: ERAS) reported Q2 2022 financial results, showcasing a cash reserve of $391 million. The company is advancing its clinical programs, expecting initial data for ERAS-007 and ERAS-601 by H2 2022. Notable collaborations include partnerships with Eli Lilly and Harvard Medical School to enhance ERAS-007 and ERAS-601's potential. R&D expenses rose to $27.5 million, driven by clinical trials, while G&A expenses increased to $8.4 million. The net loss for the quarter stands at $35.6 million, or $(0.30) per share.
Erasca has entered a clinical trial collaboration with Eli Lilly to evaluate ERAS-601, a selective SHP2 inhibitor, in the FLAGSHP-1 trial. This Phase 1/1b trial will assess ERAS-601 combined with Lilly's cetuximab for treating triple wildtype metastatic colorectal cancer and HPV-negative advanced head and neck squamous cell carcinoma. Lilly will provide cetuximab at no cost. The collaboration aims to enhance treatment responses and delay resistance onset in RAS/MAPK driven cancers, addressing significant market needs given the rising case numbers of these malignancies.
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers, will present at the 2022 Jefferies Healthcare Conference on June 10, 2022, at 8:00 AM ET in New York. CEO Jonathan E. Lim and CFO David M. Chacko will represent the company and participate in one-on-one investor meetings. A live webcast and an archived replay of the presentation will be available online, continuing until September 10, 2022. Erasca’s mission is to erase cancer through innovative therapies targeting the RAS/MAPK pathway.
Erasca, Inc. (NASDAQ: ERAS) announced a Phase 1b clinical trial for ERAS-007, an ERK1/2 inhibitor, in combination with a KRAS G12C inhibitor, targeting KRAS G12C-driven non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). This trial aims to address RAS/MAPK resistance issues linked to KRAS G12C inhibitors. Preliminary data suggests ERAS-007 may effectively counteract drug resistance mechanisms. The trial will be led by renowned investigators, with additional research planned to assess the safety and efficacy of this combination.
FAQ
What is the current stock price of Erasca (ERAS)?
What is the market cap of Erasca (ERAS)?
